A detailed history of Exodus Point Capital Management, LP transactions in Nektar Therapeutics stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 280,366 shares of NKTR stock, worth $255,133. This represents 0.0% of its overall portfolio holdings.

Number of Shares
280,366
Holding current value
$255,133
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.11 - $1.48 $311,206 - $414,941
280,366 New
280,366 $364,000
Q4 2022

Feb 13, 2023

BUY
$2.03 - $4.28 $936,745 - $1.98 Million
461,451 Added 1486.2%
492,500 $1.11 Million
Q3 2022

Nov 10, 2022

BUY
$3.04 - $5.14 $94,388 - $159,591
31,049 New
31,049 $99,000
Q2 2022

Aug 19, 2022

SELL
$3.17 - $6.17 $1.32 Million - $2.56 Million
-415,709 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$4.16 - $13.72 $1.64 Million - $5.42 Million
394,825 Added 1890.56%
415,709 $2.24 Million
Q4 2021

Feb 11, 2022

SELL
$10.83 - $18.41 $388,493 - $660,403
-35,872 Reduced 63.2%
20,884 $282,000
Q3 2021

Nov 15, 2021

BUY
$13.07 - $18.84 $180,261 - $259,841
13,792 Added 32.1%
56,756 $1.02 Million
Q2 2021

Aug 16, 2021

BUY
$16.52 - $20.4 $709,765 - $876,465
42,964 New
42,964 $737,000
Q1 2021

May 17, 2021

SELL
$16.56 - $25.46 $273,968 - $421,210
-16,544 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$15.77 - $19.03 $535,533 - $646,239
-33,959 Reduced 67.24%
16,544 $281,000
Q3 2020

Nov 16, 2020

BUY
$16.59 - $24.79 $247,937 - $370,486
14,945 Added 42.03%
50,503 $838,000
Q2 2020

Aug 14, 2020

BUY
$16.86 - $23.44 $599,507 - $833,479
35,558 New
35,558 $824,000
Q1 2020

May 15, 2020

SELL
$14.47 - $27.96 $597,307 - $1.15 Million
-41,279 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$15.87 - $23.12 $655,097 - $954,370
41,279 New
41,279 $891,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $171M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.